Shock Therapeutics Biotechnologies, Inc

Improving Trauma Care by Solving Shock

  • Stage Product In Development
  • Industry Biotechnology
  • Location Baltimore, MD, USA
  • Currency USD
  • Founded July 2017
  • Employees 4
  • Incorporation Type C-corp
  • Website shockbiotech.com

Company Summary

Shock Biotech is developing AbBu Therapy - a novel medicine for the treatment of hemorrhagic shock. Initial preclinical proof of concept studies resuscitated rats, stabilized cardiovascular function and prolonged life the full length of the study in 100% of treated rats. Shock Biotech is now focused on optimizing our antibody treatment for use by military medics in the field.

Team

  • Susan Hibbs
    CEO

    Corporate Vision
    Investor Relations
    Corporate Operations

  • Lewis Hibbs
    COO

    R&D Operations
    Computation Antibody Engineering
    Research & Writing

  • Les Johnson
    CTO

    Regulatory Lead
    Bio Manufacturing
    Quality Management

  • Daniel N Darlington PhD
    Founder & CSO

    Trauma Expert
    Bio Analytics
    In Life Modeling

  • Donald S Gann MD
    Founder - In Memoriam

    First Director of Emergency Medicine at Johns Hopkins University
    First Chair of Biomedical Engineering Department at Case Western Reserve (First of its Kind)
    Past President of American Association for the Surgery of Trauma
    Past President of Biomedical Engineering Society

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free